Gland Pharma has informed that the meeting of the board of directors of the company is scheduled on May 20, 2025 to consider and approve the audited standalone and consolidated financial results of the company for the quarter and financial year ended March 31, 2025 and recommend the payment of final dividend for FY 2024-25.
The above information is a part of company’s filings submitted to BSE.